Severe tumor lysis syndrome during the induction therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm arising from myelodysplastic/myeloproliferative neoplasms

Ken Sagou; Makoto Ito; Yuma Kawamura; Shun Ukai; Miyo Goto; Nobuaki Fukushima; Kazutaka Ozeki; Ryuichi Fukuyama; Akio Kohno

doi:10.1002/ccr3.3690

Severe tumor lysis syndrome during the induction therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm arising from myelodysplastic/myeloproliferative neoplasms

Clin Case Rep. 2020 Dec 20;9(2):878-882. doi: 10.1002/ccr3.3690. eCollection 2021 Feb.

Authors

Ken Sagou^{1

2}, Makoto Ito¹, Yuma Kawamura¹, Shun Ukai¹, Miyo Goto¹, Nobuaki Fukushima¹, Kazutaka Ozeki¹, Ryuichi Fukuyama³, Akio Kohno¹

Affiliations

¹ Department of Hematology and Oncology JA Aichi Konan Kosei Hospital Aichi Japan.
² Department of Hematology and Oncology Nagoya University Graduate School of Medicine Aichi Japan.
³ Department of Diagnostic Pathology JA Aichi Konan Kosei Hospital Aichi Japan.

Abstract

BPDCN shows clinically heterogeneous characteristics. And as other hematological malignancies, symptoms of BPDCN suggesting a high tumor burden, such as high white blood cell count or splenomegaly, should be carefully considered to prevent TLS.

Keywords: calreticulin mutation; myelodysplastic/myeloproliferative neoplasms; plasmacytoid dendritic cell neoplasm; tumor lysis syndrome.

Publication types

Case Reports